Fidelity Investments
AIM

Fidelity Investments’s AIM ImmunoTech AIM Stock Holding History

Fidelity Investments’s Portfolio AIM Stock Details AIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5
Closed -$245 – 5760
2024
Q1 		$245 Buy
+5
New +$207 ﹤0.01% 4907
2023
Q4 		– Hold
0
– – – 5403
2022
Q1 		– Sell
-1
Closed – – 5782
2021
Q4 		$0 Buy
+1
New +$155 ﹤0.01% 5271
2021
Q3 		– Hold
0
– – – 5415
2021
Q2 		– Hold
0
– – – 5259
2019
Q1 		– Hold
0
– – – 4578
2018
Q4 		– Hold
0
– – – 4538

Other funds holding AIM

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Fidelity Investments's AIM Position: Q2 2024 in Review

Fidelity Investments sold out of AIM ImmunoTech (AIM) in Q2 2024, closing a stake of 5 shares — an estimated $245 sold.

Fidelity Investments first reported a position in AIM in Q4 2021 and held it in 2 quarters. The position peaked at $245 in Q1 2024. 33 funds tracked by Wall St. Rank hold AIM as of Q2 2024.

  • Fidelity Investments reported no remaining AIM ImmunoTech position as of Q2 2024 after selling out during the quarter.
  • Fidelity Investments sold 5 AIM ImmunoTech shares in Q2 2024, an estimated $245.
  • Fidelity Investments first reported a position in AIM ImmunoTech in Q4 2021 and held it in 2 quarters.
  • Fidelity Investments's AIM ImmunoTech position peaked at $245 in Q1 2024.
  • 33 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q2 2024.

Based on Fidelity Investments's 13F filing for Q2 2024, filed 13 Aug 2024.